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Atrial fibrillation (AF) is the commonest clinically significant 
arrhythmia and is associated with significant morbidity and 
mortality.[1] Until recently, treatment options were very limited with 
the mainstay of treatment being the vitamin K antagonists (VKAs). 
The introduction of the direct-acting anticoagulants has changed 
the playing field by offering patients a choice, but at a price. The 
majority of South African (SA) patients are still deprived of this 
choice owing to financial constraints. We therefore set out to review 
oral anticoagulants and AF with a specific focus on our patient 
population. The focus of this review is to assist clinicians in their 
decision-making and prescribing practices.
Anticoagulants are categorised into two large subgroups: those 
affecting the rapidly flowing arterial systems and those affecting 
the more stasis-prone venous system. Thrombi in the venous 
system consist of a fibrin web encasing platelets and red blood 
cells. In contrast, thrombi in the arterial system consist largely of 
platelets with less fibrin. Drugs affecting coagulation are classified 
and subsequently designed to target specific sites of these thrombi. 
Drugs targeting arterial thrombi include the antiplatelet drugs 
(aspirin, clopidogrel, abciximab, eptifibatide and tirofiban) and the 
fibrinolytics (streptokinase and alteplase). Drugs targeting venous 
or stasis-induced thrombi include the traditional anticoagulants 
(heparin, low-molecular-weight (LMW) heparins and fondaparinux), 
the VKAs (warfarin), and more recently the novel or direct-acting oral 
anticoagulants (DOACs) (dabigatran, rivaroxaban and apixaban).[2]
In this review, we focus on the VKA warfarin and the DOACs 
dabigatran and rivaroxaban and their use in NVAF in the SA state 
sector. NVAF is common, and with the arrival of the DOACs, doctors 
in the public sector need to familiarise themselves with these drugs 
and their risks and benefits.
Methods
A systematic literature search was conducted of PubMed, Google 
Scholar and the TRIP database. The following Medical Subject 
Heading (MeSH) terms were used: ‘anticoagulants’, ‘vitamin K 
antagonists’, ‘warfarin’, ‘direct or novel acting anticoagulants’, 
‘dabigatran’, ‘rivaroxaban’, ‘apixaban’, ‘pharmacology’, ‘monitoring’, ‘cost 
effectiveness’, ‘atrial fibrillation’, ‘risk stratification’, ‘guidelines’ and 
‘South Africa’. Other databases consulted included the universi ties of 
Liverpool and California’s antiretroviral drug databases, Statistics 
South Africa, and the Joint United Nations Programme on HIV/
AIDS (UNAIDS) regarding HIV statistics. Printed pharmacology 
textbooks were also consulted where electronic text was unclear.
Systematic reviews, randomised controlled trials, cohorts and 
case-control studies were included. Only studies published in English 
were included. Original research was included then compared with 
research or study types that best addressed the specific research 
questions. The research question for each topic in this review 
revolved around what the current gold standard is and how we 
can implement it in our setting. When available, SA literature was 
included. Case studies and case series were excluded, as were studies 
published in foreign languages and those not related to AF. Research 
published after 31 December 2017 was not included.
Results and discussion
To determine whether we can successfully introduce the DOACs 
in our setting, we reviewed a total of 113 references and included 
40 publications that met our inclusion criteria. Of the 40 articles 
included, seven (see Table 4) directly addressed our research question: 
Will the use of DOACs be more cost-effective than warfarin for non-
valvular AF (NVAF) in the public healthcare setting in SA? Fig. 1 
represents a visual illustration of articles included and excluded.[3]
Pharmacology and monitoring of warfarin and DOACs
Warfarin is a VKA and coumarin derivative acting on the cyclic 
interconversion of vitamin K in the liver. VKAs block γ-carboxyla-
tion of glutamate residues and inhibit vitamin K reductase. This 
process results in partially carboxylated and decarboxylated vitamin 
K-dependent clotting factors (II, VII, IX, X). These proteins lose their 
procoagulant effect because carboxylation is required to bring about 
a calcium-dependent conformational change in the coagulation 
proteins.[4] Without this conformational change, coagulation proteins 
cannot bind to cofactors on phospholipid surfaces and coagulation 
fails. The anticoagulant proteins C and S are also inactivated by 
this process and can lead to a prothrombotic state, which is in most 
circumstances overcome by the effect of the VKAs.[5] The intensity of 
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coagulation is monitored using the patient’s 
prothrombin time (PT) and is standardised 
by an international normalised ratio (INR) 
test.[5] The INR is calculated as follows:[6] 
INR = (patient PT/mean normal PT)ISI.
Warfarin should be taken once a day, at the 
same time every day. Two to three doses of 
warfarin are necessary for the INR to reach 
the therapeutic range. This delay in effect can 
be attributed to the different half-lives of the 
clotting factors. The vitamin K-dependent 
factors detected by the PT test undergo 
reduction at a rate proportional to their half-
lives. Factor VII is reduced first, followed by 
factors X and II. The mean therapeutic INR 
is 2.5 (range 2.0 - 3.0), with the exception of a 
mitral prosthesis, which requires a mean INR 
of 3.0 (range 2.5 - 3.5).[7]
INR monitoring should be commenced 
after two to three doses of treatment and 
differs for inpatients and outpatients. 
Inpatients require daily INRs until the 
therapeutic range has been achieved and 
maintained for 2 days. Outpatients can 
be monitored every 2 days until a stable 
INR has been achieved. Once the INR is 
stable, intervals between monitoring should 
not exceed 4 weeks. Current guidelines 
recommended monitoring intervals of up 
to 12 weeks in stable patients.[7] Evidence 
suggests that more frequent monitoring 
results in more time in the therapeutic 
range (TTR).[8] Patients at an increased 
risk of thromboembolic events require 
dual anticoagulation with LMW heparin or 
unfractionated heparin after being initiated 
on warfarin, because of warfarin’s effect on 
protein C and S and the 2 - 3-day delay 
in reaching the therapeutic range. Dual 
anticoagulation can be stopped once the 
INR has been within the desired thera-
peutic range for 2 days or when two INR 
measurements taken 24 hours apart are 
within the therapeutic range. Patients with 
stable conditions (including chronic AF) 
can be started on VKAs on an outpatient 
basis without additional anticoagulant cover 
at a loading dose of 10 mg for healthy 
individuals.[7]
Warfarin is also known to interact with 
numerous drugs and with foods such as 
green leafy vegetables. These vegetables have 
naturally high vitamin K levels and interact 
with VKAs.[9] Various drugs affect warfarin’s 
metabolism, either potentiating or reducing 
its effectiveness. Warfarin consists of an S- 
and an R-enantiomer. The S-enantiomer is 
the more potent of the two and drugs such 
as clotrimazole and metronidazole, which 
inhibit its metabolism, potentiate warfarin’s 
effects.[5,10] Drugs affecting the R-enantiomer, 
such as the proton-pump inhibitor omepra-
zole and the H2 antagonist cimetidine, have 
a lesser effect on PT and INR. Long-term 
paracetamol and alcohol use have been found 
to alter the clearance of warfarin, although 
short-term alcohol use was found to have 
a negligible effect on PT. Chronic alcohol 
use increases the clearance of warfarin and 
lowers the INR.[11] Chronic paracetamol use 
increases the anticoagulant effect of warfarin 
through a toxic metabolite that inhibits 
vitamin K oxide reductase.[12] Rifampicin, 
barbi turates, carbamazepine, griseofulvin, 
amino glutethimide, nafcillin and dicloxa-
cillin are powerful inducers of warfarin meta-
bolism and decrease its effectiveness.[13]
Antiretroviral medication influences 
war farin concentration to various degrees, 
but high-quality, peer-reviewed evidence 
of the exact mechanisms is lacking. The 
protease inhibitors appear to decrease the 
effects of warfarin, with ritonavir decreasing 
R-enantiomer levels and lopinavir inducing 
CYP2C9.[14] Nevirapine and efavirenz alter 
warfarin levels to various degrees through 
complex mechanisms, and frequent drug 
monitoring is required.[15] Currently there is 
little evidence to suggest that the common 
nucleoside/nucleotide analogues have a 
clinically significant effect on a patient’s 
INR.[15,16]
The DOACs, which include dabigatran, 
rivaroxaban and apixaban, were designed 
because of the limitations associated with 
warfarin use. Dabigatran or the prodrug 
dabigatran etexilate is a reversible direct 
thrombin inhibitor and prevents the 
conversion of fibrinogen to fibrin. [17] 
Because this drug causes reversible 
inhibition of thrombin, it leaves a small 
amount of free active thrombin to assist with 
haemostasis. [17] Routine drug monitoring is 
not recommended by the manufacturer or by 
the American College of Chest Physicians, 
as dabigatran has a relatively predictable 
pharmacological profile. Ecarin clotting time 
can be used to monitor the effect of this drug, 
but neither the PT nor the activated partial 
thromboplastin time (aPTT) can be used, 
as there is no linear correlation between 
dabigatran concentration and aPTT levels. [18] 
As dabigatran is renally excreted, some 
authors do recommend drug monitoring in 
patients with renal impairment.[19]
Rivaroxaban is a direct and reversible 
inhibitor of factor Xa that inhibits both 
free and clot-bound factor Xa, resulting in 
its anticoagulant effect. As with dabigatran 
no routine drug monitoring is required, 
although unlike dabigatran, rivaroxaban has 
a predictable effect on the PT and to a 
lesser extent the aPTT.[20] Apixaban, like 
rivaroxaban, is a factor Xa inhibitor.[20]
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Fig. 1. Flow diagram of literature reviewed to determine the end-point.
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Managing a patient who requires anticoagulation
Anticoagulation is complex, as there are several indications, agents 
and dosing regimens to choose from. In the SA public healthcare 
sector these complexities are exacerbated by our diverse patient 
populations, some of whom have multiple comorbidities, and 
limited access to the various anticoagulants available. Numerous 
international guidelines are available for outpatient anticoagulation 
and prevention of thromboembolic events. Guidelines that are 
widely used include the 2012 American College of Chest Physicians 
(ACCP) (9th edition)[21] and the 2011 British Journal of Haematology 
(BJH) guidelines.[22]
The 2011 BJH guidelines on oral anticoagulation with warfarin 
are widely used in SA and are often referenced by the National 
Health Laboratory Service. Differences between these two guidelines 
are set out in Table 1. Most clinicians refer to the ACCP guidelines 
when making a decision on managing patients who require 
anticoagulation, as these guidelines are more comprehensive than 
the BJH guidelines.
There are several noteworthy updates to the 9th edition of the 
ACCP guidelines, and one that will have a major effect on patient 
load and expenses is the frequency of INR monitoring. Traditionally 
patients are seen at 4-week intervals to check whether their INRs are 
in the therapeutic range, but the update recommends that this may be 
lengthened to 12 weeks. Patients become eligible for this prolonged 
follow-up if they have consistently stable INRs without requiring dose 
adjustment.[7] The implementation of such a recommendation has 
the potential to significantly decrease cost and patient load on the 
healthcare system. Our own research has shown that a major driver of 
cost is number of clinic visits in combination with monthly INRs, and 
a major driver of patient dissatisfaction is number of consultations 
and venepunctures.[23] The ACCP guidelines recommend using 
dabigatran 150 mg twice daily instead of warfarin for treating NVAF 
for patients at intermediate and high risk for stroke (recommendation 
2.1.11, grade 2B recommendation and level of evidence).[21]
Unfortunately, there are no recent anticoagulation guidelines specific 
to SA. Implementing North American and European guide lines is 
difficult in the SA setting owing to the high prevalence of HIV, as 
these new drugs are poorly studied in this subgroup of patients. In 
2016 SA had an estimated 7.1 million people living with HIV, 19% of 
the global HIV population, of whom 56% had access to antiretroviral 
treatment.[24] This population of patients are at risk of developing 
deep-vein thrombosis.[25]
Risk stratification and initiation of treatment
Risk stratification is particularly useful in deciding when to initiate 
treatment in patients with NVAF. Several scoring systems have 
been devised to better manage patients with NVAF. The two most 
popular are the CHA2DS2-VASc and CHADS2 scores, CHA2DS2-
VASc being the updated scoring system of the original CHADS2 
score.[26]
Table 2 highlights the different components of the CHA2DS2-
VASc score. CHA2DS2-VASc is an acronym that helps to determine 
a patient’s annual stroke risk.[26] The maximum score is 9 points.
Table 2. CHA2DS2-VASc score
Risk factor Score
Congestive heart failure (C) 1
Hypertension (H): Blood pressure consistently  
>140/90 mmHg (or treated hypertension on medication)
1
Age ≥75 years (A) 2
Diabetes mellitus (D) 1
Prior stroke or TIA or thromboembolism (S) 2
Vascular disease (V) 1
Age 65 - 74 years (A) 1
Sex category (female sex) (Sc) 1
TIA = transient ischaemic attack.
Table 1. Differences between guidelines on anticoagulation with warfarin
2011 BJH guidelines[22] 2012 ACCP guidelines (9th edition)[21]
Indications VTE, APS, AF, cardioversion, valvular heart 
disease and prosthetic valves, peripheral 
vascular disease and myocardial infarction 
and cardiomyopathy
DVT/PE, AF or atrial flutter, CAD, valvular and 
rheumatic heart disease, and prevention of VTE 
for orthopaedic surgery
Initiation of treatment No evidence to suggest that a 10 mg loading 
dose is superior to a 5 mg loading dose
In healthy outpatients with VTE, initiating 
treatment at a dose of 10 mg daily for 2 days 
followed by dosing based on INR measurements, 
rather than starting with the estimated 
maintenance dose, is recommended. This decreases 
the number of doses of LMWH and achieves a 
therapeutic INR sooner.
Management of bleeding and of an 
elevated INR without bleeding
Major bleeding
• Administer 25 - 50 U/kg of four-factor PC 
AND 5 mg IV vitamin K
Non-major bleed
• Administer 1 - 3 mg of IV vitamin K
Non-bleeding patient
• INR 5.0 - 7.9: withhold 1 - 2 doses of 
warfarin, reduce maintenance dose and 
investigate cause of elevated INR
• INR >8.0: 1 - 5 mg of oral vitamin K
VKA-associated major bleed
• Rapid reversal with four-factor PC rather 
than with plasma, and vitamin K 5 - 10 mg 
administered by slow IV injection 
INR >10.0 without bleeding
• Oral vitamin K 2 - 2.5 mg 
INR 4.5 - 10.0 without major bleeding
• No evidence to support routine use of vitamin K
BJH = British Journal of Haematology; ACCP = American College of Chest Physicians; VTE = venous thromboembolism; APS = antiphospholipid syndrome; AF = atrial fibrillation;  
DVT = deep-vein thrombosis; PE = pulmonary embolus; CAD = coronary artery disease; INR = international normalised ratio; LMWH = low-molecular-weight heparin;  
PC = prothrombin complex; IV = intravenous; VKA = vitamin K antagonist.
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These models incorporate the major risk 
factors for ischaemic stroke and give an 
unadjusted ischaemic stroke rate as a per-
centage per year.[27] A score of 0 requires no 
anticoagulation, although there are excep-
tions to this rule. A score of ≥2 (high risk 
for thromboembolism) is a strong indica-
tion for anticoagulation with either DOACs 
or VKAs, while there is some controversy 
regarding a score of 1 (intermediate risk for 
thromboembolism). Some clinicians choose 
to anticoagulate all patients with a score of 1, 
while others choose to withhold therapy.[28]
Patients who qualify for and are initiated 
on oral anticoagulation have an increased risk 
of bleeding. This increased risk of bleeding 
is usually offset by the benefit obtained from 
thromboembolism risk reduction, although 
there are certain instances where this is not 
the case. For this reason, the HAS-BLED 
scoring system (Table 3) was developed. The 
HAS-BLED score is a simple and practical 
score that is used to determine a patient’s 
annual bleeding risk. Oral anticoagulation 
bleeding risk outweighs the benefits of 
treatment if the HAS-BLED score exceeds the 
CHADS2 score in patients with a CHADS2 
score >2. In patients with a CHADS2 score of 
1, a HAS-BLED score >2 should prompt the 
doctor not to consider oral anticoagulation. [29] 
The maximum score is also 9 points. Fig. 2 
illustrates a practical approach to treating 
patients with NVAF by combining the HAS-
BLED and CHA2DS2-VASc scores.
Valvular AF
Rheumatic and mechanical prosthetic 
heart valves, with or without comorbid AF, 
re quire anticoagulation with VKAs. Dabi-
gatran is contraindicated in patients with 
prosthetic heart valves, and rivaroxaban and 
apixaban are unstudied in this population 
group. The RE-ALIGN trial was stopped 
during phase two owing to an increase in 
thromboembolic events and bleeding in 
the dabigatran subgroup.[30] Investigators 
have attempted to explain this complication 
by suggesting that there was an incorrect 
selection of dabigatran trough levels and a 
possible decrease in dabigatran’s effectiveness 
during a postoperative hypercoagulable 
state. [31] A notable exception to this rule is the 
bioprosthetic valves, which carry a relatively 
low risk of thrombosis, but there is limited 
evidence to suggest that some DOACs may 
be a suitable alternative to conventional 
anticoagulation in these patients.[32]
Effectiveness of the available oral 
anticoagulants
The ROCKET-AF,[33] ARISTOTLE[34] and 
RE-LY[35] studies have found the DOACs 
to be non-inferior to warfarin, and in some 
cases superior. Dabigatran 150 mg twice daily 
was associated with a stroke rate of 1.11% per 
year for patients with NVAF compared with 
a stroke rate of 1.69% per year for patients 
on dose-adjusted warfarin (p<0.001). Rates 
of major bleeding for dabigatran 150 mg and 
dose-adjusted warfarin appear to be similar, 
but there is a significantly decreased risk 
of life-threatening intracranial bleeds with 
dabigatran 110 mg (0.12%; p<0.001) and 
150 mg (0.10%; p<0.001) compared with 
warfarin (0.38%).[35]
Rivaroxaban showed similar results, 
with a significant reduction in fatal bleeds 
in comparison with warfarin (0.2% v. 
0.5%; p=0.003). An important finding 
of the ROCKET-AF trial was the TTR 
for patients on warfarin, which was only 
55%.[33] Some authors have mentioned that 
this is a confounding factor in ROCKET-
AF. There is no internationally acceptable 
TTR for clinical trials, although Connolly 
et al.[36] showed that there is little benefit 
of oral anticoagulation over conventional 
antiplatelet therapy if the TTR is <58 - 65%. 
A similar comment can be made when 
evaluating the ARISTOTLE trial in which 
18 201 patients were enrolled. Apixaban was 
found to be more effective than warfarin in 
preventing stroke and systemic embolism 
with lower rates of bleeding. Patients on 
warfarin had a mean TTR of 62% and a 
median TTR of 66%.[34] Possible explanations 
for warfarin’s TTR in this study include non-
compliance, drug-drug interaction, drug-
food interactions and patient comorbidities.
The DOACs require less monitoring and 
have fewer drug interactions than the VKAs, 
but they do have distinct disadvantages. 
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What is the 
CHA2DS2-VASc 
score?
0                                                   1                                                 ≥2
No routine 
anticoagulation 
necessary
The risk/benet ratio varies 
depending on the specic risk 
factor for stroke. The choice regarding 
anticoagulation is left to the doctor's
 discretion in consultation with the 
patient's needs and expectations
Does the HAS-BLED 
score exceed or equal 
the CHA2DS2-VASc score?
Yes                                            No
A patient at high risk 
for bleeding should be 
counselled regarding 
the risk of systemic 
embolism and stroke v. 
bleeding risk, and the 
decision whether to 
anticoagulate or omit 
treatment should be a 
mutual one where 
practical
Anticoagulation 
is recommended
Fig. 2. A practical approach to anticoagulation in non-valvular atrial fibrillation.
Table 3. HAS-BLED score
Risk factor Score
Hypertension (H) 1
Abnormal (A) renal and liver function (1 point each) 1 or 2
Stroke (S) 1
Bleeding history (B) 1
Labile INRs (L) 1
Elderly (E) 1
Drugs (D) or alcohol (1 point each) 1 or 2
INR = international normalised ratio.
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A major concern for healthcare providers is the absence of a readily 
available antidote or reversal agent. A reversal agent for dabigatran 
is available in the form of idarucizumab (Praxbind), a monoclonal 
antibody, but there are none for any of the factor Xa inhibitors.[37] 
Currently Praxbind is available in SA as a section 21 drug at a cost of 
ZAR32 000 including value-added tax. Section 21 of the Medicines 
and Related Substances Control Act (No. 101 of 1965) authorises the 
sale of unregistered orthodox medicine, complementary medicine, 
veterinary medicine or devices for certain purposes.[38] Management 
of major bleeds revolves around haemodialysis, administering an 
antifibrinolytic agent and prothrombotic clotting factors.[39] High-
quality evidence is lacking for these interventions.
Warfarin has three distinct advantages over these drugs: no dose 
adjustment is required when treating patients with renal failure, 
therapeutic monitoring is readily accessible, and the antidote is readily 
available.
Cost and cost-effectiveness
In a resource-constrained setting such as SA, costs need to be balanced 
against efficacy and quality of life. This is determined by the cost-
effectiveness ratio (CER) per quality-adjusted life year (QALY). A 
CER of <50 000 USD is considered desirable and a CER >100 000 
USD is considered less desirable. In the UK, a CER of <30 000 GBP is 
desirable.[40] Published cost-effectiveness analyses have been conducted 
using mostly Markov decision models and estimated costs. Harrington 
et al.[41] concluded that dabigatran, rivaroxaban and apixaban are all 
cost-effective alternatives to warfarin, with none of these drugs having 
a CER of >100 000 USD. Freeman et al.[42] concluded that high-dose 
dabigatran had a CER of USD45 372 per QALY, and Shah and Gage[43] 
calculated the CER at USD86 000 per QALY.
In 2013, Coyle et al.[44] conducted one of the first cost-effectiveness 
analyses of the three new anticoagulants apixaban, dabigatran and 
rivaroxaban. They came to a similar conclusion as previous authors, 
with high-dose dabigatran the dominant treatment option and a cost-
effective alternative to warfarin at a CER of USD20 797. Apixaban was 
considered as a cost-effective alternative at a CER of USD24 312. Low-
dose dabigatran and rivaroxaban were found to have an unfavourable 
cost-effectiveness analysis, with a CER of >50 000 USD.[44] Canestaro 
et al.[45] published a cost-effectiveness analysis that concluded that the 
only cost-effective treatment option was apixaban. In their analyses 
the CERs of apixaban, rivaroxaban and dabigatran were USD93 063, 
USD111 465 and USD140 557, respectively. Their results were in 
contrast to previous published studies and concluded that both 
dabigatran and rivaroxaban, although contributing significantly to 
QALYs, were not cost-effective treatment options. These results 
are largely due to the authors assigning a price of USD4 per month 
for warfarin, in contrast to other authors who assigned it a cost of 
USD30 per month.[45] These studies affirm that there is still much 
uncertainty when determining whether these drugs are cost-effective 
alternatives to warfarin. Reasons for this uncertainty include authors 
using different patient populations and assigning different costs under 
different economic climates. Table 4 compares the cost-effectiveness 
studies used in this review.
As a by-product of the cost-effectiveness analyses, these studies 
did emphasise one important point: that the DOACs provide patients 
with a superior quality of life compared with warfarin. QALYs gained 
varied between different studies, but it appears that the DOACs were 
consistently superior to warfarin regardless of individual CHADS2 
scores.[41,42,46] In their base-case analysis, Harrington et al.[41] calculated 
that dabigatran 150 mg added 8.41 QALYs and apixaban 5 mg 
8.47  QALYs compared with 7.97 QALYs for dose-adjusted warfarin. 
This is in keeping with the results of Freeman et al.,[42] who concluded 
that high-dose dabigatran contributed an additional 0.56 QALYs in 
comparison with warfarin. Rivaroxaban 20 mg was found to contribute 
0.22 QALYs when compared with dose-adjusted warfarin.[46] These 
findings are broadly in keeping with the results of Coyle et al.,[44] who 
showed that dabigatran 150 mg was the dominant treatment option in 
terms of QALYs and CER, followed closely by apixaban, rivaroxaban 
and dabigatran 110 mg.
Cost implications for SA
Little research has been conducted on the cost-effectiveness of the 
DOACs in an SA setting. Bergh et al.[47] conducted a cost-effectiveness 
analysis of dabigatran as first-line therapy for stroke prevention in 
AF in the SA private sector. They estimated an incremental CER 
of ZAR93 290 per QALY when comparing dose-adjusted warfarin 
with dabigatran. They concluded that dabigatran is a cost-effective 
alternative to warfarin in the SA private sector.[47] Their economic 
appraisal is useful, but it is difficult to interpret in the context of the 
SA public sector. No threshold amount exists for willingness to pay 
per QALY in SA. If one were to convert the current US threshold 
of USD100 000 to ZAR, at the exchange rate at the time of writing 
(ZAR13.50 per USD, 15 December 2017), South Africans would be 
expected to pay ZAR1 350 000 per QALY gained. In a country with 
an unemployment rate of 27.7%, ZAR93 290 per QALY would be 
unaffordable for a large portion of the population.[48] Symons[49] appears 
to have come to a similar conclusion in his review article, stating that 
for the time being the DOACs are too expensive to introduce in the 
vast majority of SA population groups. These findings are in keeping 
with our own cost-effectiveness analysis. Warfarin was found to be 
significantly more cost-effective than the DOACs, even when a wide 
range of warfarin-related expenses was included.[23]
Study limitations
This review is not intended to be a comprehensive account of all 
available literature on anticoagulants, but rather to highlight the 
difficulties and limitations associated with prescribing anticoagulants 
in SA and to provide some clarity to the clinician.
The major limitation of this review is the paucity of SA literature. 
The context in which care is rendered in developed countries differs 
from that in SA, and implementing their recommendations in our 
public healthcare setting would inevitably prove challenging. The 
international literature and research on this topic are constantly 
evolving, so the potential for research included in this review to 
become outdated is a further limiting factor.
Conclusions
Anticoagulation is an ever-evolving area with constant updates on 
new drugs and management protocols. The challenge for doctors in 
SA is the lack of substantive data to support the use of the DOACs 
for the majority of patients who access care in the public sector. For 
the foreseeable future, warfarin will remain the mainstay of oral 
anticoagulation. It is inexpensive and readily available, and doctors 
are comfortable prescribing it. However, doctors should familiarise 
themselves with the DOACs, as they have distinct advantages over 
warfarin and their availability will increase as cheaper generic 
alternatives become available.
Acknowledgements. DJL thanks his wife Dr R Laäs for assisting with editing.
Author contributions. DJL was the principal investigator and MN the 
research supervisor.
Funding. A research grant was obtained from the South African Medical 
Association. The authors state that this grant had no influence on the results 
and conclusions of this article.
Conflicts of interest. None.
REVIEW
645       August 2018, Vol. 108, No. 8
Ta
bl
e 4
. C
om
pa
ri
so
n 
of
 co
st
-e
ffe
ct
iv
en
es
s s
tu
di
es
Au
th
or
s, 
ye
ar
, 
stu
dy
 n
am
e, 
re
fe
re
nc
e 
no
.
H
ar
rin
gt
on
 A
R,
 
A
rm
str
on
g 
EP
, N
ol
an
 P
E,
 
M
al
on
e 
D
C.
 2
01
3.
 C
os
t-
ef
fe
ct
iv
en
es
s o
f a
pi
xa
ba
n,
 
da
bi
ga
tr
an
, r
iv
ar
ox
ab
an
, 
an
d 
w
ar
fa
rin
 fo
r s
tro
ke
 
pr
ev
en
tio
n 
in
 at
ria
l 
fib
ril
la
tio
n[
41
]
Sh
ah
 S
V,
 G
ag
e 
BF
. 2
01
1.
 
C
os
t-e
ffe
ct
iv
en
es
s o
f 
da
bi
ga
tr
an
 fo
r s
tro
ke
 
pr
op
hy
la
xi
s i
n 
at
ria
l 
fib
ril
la
tio
n[
43
]
Fr
ee
m
an
 JV
, Z
hu
 R
P, 
O
w
en
s D
K,
 et
 a
l. 
20
11
. 
C
os
t-e
ffe
ct
iv
en
es
s o
f 
da
bi
ga
tr
an
 co
m
pa
re
d 
w
ith
 w
ar
fa
rin
 fo
r s
tro
ke
 
pr
ev
en
tio
n 
in
 at
ria
l 
fib
ril
la
tio
n[
42
]
C
oy
le
 D
, C
oy
le
 K
, 
Ca
m
er
on
 C
, e
t a
l. 
20
13
. 
C
os
t-e
ffe
ct
iv
en
es
s o
f 
ne
w
 o
ra
l a
nt
ic
oa
gu
la
nt
s 
co
m
pa
re
d 
w
ith
 w
ar
fa
rin
 
in
 p
re
ve
nt
in
g 
str
ok
e 
an
d 
ot
he
r c
ar
di
ov
as
cu
la
r 
ev
en
ts 
in
 p
at
ie
nt
s w
ith
 
at
ria
l f
ib
ril
la
tio
n[
44
]
Ca
ne
sta
ro
 W
J, 
Pa
tr
ic
k 
A
R,
 A
vo
rn
 J,
 et
 a
l. 
20
13
. 
C
os
t-e
ffe
ct
iv
en
es
s o
f 
or
al
 a
nt
ic
oa
gu
la
nt
s 
fo
r t
re
at
m
en
t o
f a
tr
ia
l 
fib
ril
la
tio
n[
45
]
Le
e 
S,
 A
ng
la
de
 M
W
, 
Ph
am
 D
, P
isa
ca
ne
 R
, 
K
lu
ge
r J
, C
ol
em
an
 C
I. 
20
12
. C
os
t-e
ffe
ct
iv
en
es
s 
of
 ri
va
ro
xa
ba
n 
co
m
pa
re
d 
to
 w
ar
fa
rin
 fo
r s
tro
ke
 
pr
ev
en
tio
n 
in
 at
ria
l 
fib
ril
la
tio
n[
46
]
Be
rg
h 
M
, M
ar
ai
s C
A
, 
M
ill
er
-Ja
ns
ön
 H
, S
al
ie
 
F, 
St
an
de
r M
P. 
20
13
. 
Ec
on
om
ic
 ap
pr
ai
sa
l 
of
 d
ab
ig
at
ra
n 
as
 fi
rs
t-
lin
e 
th
er
ap
y 
fo
r s
tro
ke
 
pr
ev
en
tio
n 
in
 at
ria
l 
fib
ril
la
tio
n[
47
]
St
ud
y 
po
pu
la
tio
n
A
 h
yp
ot
he
tic
al
 co
ho
rt
 o
f 
70
-y
ea
r-
ol
d 
pa
tie
nt
s w
ith
 
N
VA
F, 
at
 a
n 
in
cr
ea
se
d 
ris
k 
of
 st
ro
ke
A
 h
yp
ot
he
tic
al
 co
ho
rt
 
of
 7
0-
ye
ar
-o
ld
 p
at
ie
nt
s 
w
ith
 A
F 
w
ith
 a
 m
od
er
at
e 
ris
k 
of
 st
ro
ke
 a
nd
 n
o 
co
nt
ra
in
di
ca
tio
n 
to
 
an
tic
oa
gu
la
nt
 th
er
ap
y
Th
e 
RE
-L
Y 
tr
ia
l a
nd
 
ot
he
r p
ub
lis
he
d 
stu
di
es
 
of
 a
nt
ic
oa
gu
la
tio
n
A
 ty
pi
ca
l p
at
ie
nt
 p
ro
fil
e 
fro
m
 th
e 
RE
-L
Y 
stu
dy
 
w
as
 a
do
pt
ed
: a
ve
ra
ge
 a
ge
 
72
 y
ea
rs
 w
ith
 n
o 
pr
ev
io
us
 
str
ok
e 
or
 m
yo
ca
rd
ia
l 
in
fa
rc
tio
n
A
 th
eo
re
tic
al
 co
ho
rt
 
of
 7
0-
ye
ar
-o
ld
 p
at
ie
nt
s 
w
ith
 a
n 
av
er
ag
e 
CH
A
D
S 2
 
sc
or
e 
of
 2
A
 co
ho
rt
 o
f p
at
ie
nt
s 
ag
ed
 6
5 
ye
ar
s w
ith
 A
F 
at
 h
ig
h 
ris
k 
of
 st
ro
ke
 
(C
H
A
D
S 2
 sc
or
e 
3)
 a
nd
 
no
 co
nt
ra
in
di
ca
tio
ns
 to
 
an
tic
oa
gu
la
tio
n
A
 co
st-
ef
fe
ct
iv
en
es
s 
m
od
el 
ba
se
d 
on
 th
e 
ou
tc
om
e 
of
 th
e 
RE
-L
Y 
tr
ia
l i
n 
20
10
 a
nd
 
po
pu
la
te
d 
w
ith
 S
A
 
m
or
ta
lit
y 
an
d 
co
st 
da
ta
M
ai
n 
fin
di
ng
Th
e 
N
O
AC
s e
va
lu
at
ed
 
in
 th
is 
stu
dy
 w
er
e 
m
or
e 
co
st-
ef
fe
ct
iv
e 
tre
at
m
en
t 
op
tio
ns
 th
an
 w
ar
fa
rin
 
fo
r s
tro
ke
 p
re
ve
nt
io
n 
in
 
pa
tie
nt
s w
ith
 N
VA
F.
D
ab
ig
at
ra
n 
15
0 
m
g 
(tw
ic
e 
da
ily
) w
as
 
co
st-
ef
fe
ct
iv
e 
in
 A
F 
po
pu
la
tio
ns
 at
 h
ig
h 
ris
k 
of
 h
ae
m
or
rh
ag
e 
or
 h
ig
h 
ris
k 
of
 st
ro
ke
 u
nl
es
s I
N
R 
co
nt
ro
l w
ith
 w
ar
fa
rin
 
w
as
 e
xc
el
le
nt
. W
ar
fa
rin
 
w
as
 co
st-
ef
fe
ct
iv
e 
in
 
m
od
er
at
e-
ris
k 
A
F 
po
pu
la
tio
ns
 u
nl
es
s I
N
R 
co
nt
ro
l w
as
 p
oo
r.
In
 p
at
ie
nt
s a
ge
d 
≥6
5 
ye
ar
s w
ith
 N
VA
F 
 
at
 in
cr
ea
se
d 
ris
k 
fo
r 
str
ok
e 
(C
H
A
D
S 2
 
sc
or
e 
1 
or
 e
qu
iv
al
en
t),
 
da
bi
ga
tr
an
 m
ay
 b
e 
a 
co
st-
ef
fe
ct
iv
e 
al
te
rn
at
iv
e 
to
 w
ar
fa
rin
 d
ep
en
di
ng
 o
n 
pr
ic
in
g 
in
 th
e 
U
SA
.
Re
su
lts
 w
er
e 
hi
gh
ly
 
se
ns
iti
ve
 to
 p
at
ie
nt
 
ch
ar
ac
te
ris
tic
s. 
Ri
va
ro
xa
ba
n 
an
d 
da
bi
ga
tr
an
 1
10
 m
g 
w
er
e 
un
lik
ely
 to
 b
e 
co
st-
ef
fe
ct
iv
e. 
Fo
r d
iff
er
en
t 
ch
ar
ac
te
ris
tic
s, 
ap
ix
ab
an
 
or
 d
ab
ig
at
ra
n 
15
0 
m
g 
w
er
e 
op
tim
al
.
Ap
ix
ab
an
 se
em
s t
o 
be
 th
e 
op
tim
al
 a
nt
ic
oa
gu
la
tio
n 
str
at
eg
y. 
W
ar
fa
rin
 se
em
s 
to
 b
e 
th
e 
op
tim
al
 ch
oi
ce
 
in
 a
n 
eq
ua
l n
um
be
r o
f 
sim
ul
at
io
ns
. A
s a
 re
su
lt,
 
al
th
ou
gh
 a
ll 
th
e 
N
O
AC
s 
pr
od
uc
e 
gr
ea
te
r q
ua
lit
y-
ad
ju
ste
d 
lif
e 
ex
pe
ct
an
cy
 
th
an
 w
ar
fa
rin
, t
he
y 
m
ay
 
no
t r
ep
re
se
nt
 g
oo
d 
va
lu
e 
fo
r m
on
ey
.
Ri
va
ro
xa
ba
n 
m
ay
 b
e 
a 
co
st-
ef
fe
ct
iv
e 
al
te
rn
at
iv
e 
to
 w
ar
fa
rin
 in
 p
at
ie
nt
s 
w
ith
 A
F 
re
ga
rd
le
ss
 o
f 
ba
se
lin
e 
isc
ha
em
ic
 st
ro
ke
 
ris
k.
D
ab
ig
at
ra
n 
as
 fi
rs
t-l
in
e 
tre
at
m
en
t c
om
pa
re
d 
w
ith
 w
ar
fa
rin
 fo
r t
he
 
us
e 
of
 st
ro
ke
 p
re
ve
nt
io
n 
in
 p
at
ie
nt
s w
ith
 A
F 
w
as
 d
ee
m
ed
 co
st-
ef
fe
ct
iv
e 
w
he
n 
us
ed
 
in
 a
cc
or
da
nc
e 
w
ith
 it
s 
re
gi
ste
re
d 
in
di
ca
tio
n 
in
 
th
e 
SA
 p
riv
at
e 
se
ct
or
.
Fu
nd
in
g
N
on
e 
di
sc
lo
se
d
BF
G
 w
as
 su
pp
or
te
d 
by
 
th
e 
A
m
er
ic
an
 H
ea
rt
 
A
ss
oc
ia
tio
n.
 S
V
H
 
w
as
 su
pp
or
te
d 
by
 th
e 
Kn
ow
lto
n 
Fo
un
da
tio
n 
an
d 
a 
fe
llo
w
sh
ip
 at
 
W
as
hi
ng
to
n 
U
ni
ve
rs
ity
 in
 
St
 L
ou
is,
 U
SA
A
m
er
ic
an
 H
ea
rt
 
A
ss
oc
ia
tio
n 
an
d 
Ve
te
ra
ns
 A
ffa
irs
 H
ea
lth
 
Se
rv
ic
es
 R
es
ea
rc
h 
an
d 
D
ev
elo
pm
en
t S
er
vi
ce
A
 g
ra
nt
 fr
om
 th
e 
Ca
na
di
an
 In
sti
tu
te
s o
f 
H
ea
lth
 R
es
ea
rc
h 
D
ru
g 
Sa
fe
ty
 a
nd
 E
ffe
ct
iv
en
es
s 
N
et
w
or
k
U
nr
es
tr
ic
te
d 
re
se
ar
ch
 
gr
an
t f
ro
m
 C
VS
 
Ca
re
m
ar
k 
to
 B
rig
ha
m
 
an
d 
W
om
en
’s 
H
os
pi
ta
l, 
U
SA
CI
C 
ha
s r
ec
ei
ve
d 
re
se
ar
ch
 fu
nd
in
g 
fro
m
 
Ja
ns
se
n 
Ph
ar
m
ac
eu
tic
al
s
Th
e 
stu
dy
 w
as
 
fu
nd
ed
 b
y 
Bo
eh
rin
ge
r 
In
ge
lh
ei
m
 S
A
C
on
fli
ct
 o
f 
in
te
re
st
N
on
e 
di
sc
lo
se
d
N
on
e 
di
sc
lo
se
d
N
on
e 
m
en
tio
ne
d
Pu
bl
ic
at
io
n 
of
 th
e 
stu
dy
 re
su
lts
 w
as
 n
ot
 
co
nt
in
ge
nt
 o
n 
th
e 
sp
on
so
r’s
 ap
pr
ov
al
 
or
 ce
ns
or
sh
ip
 o
f t
he
 
m
an
us
cr
ip
t
N
on
e 
di
sc
lo
se
d
CI
C 
an
d 
JK
 w
er
e 
m
em
be
rs
 o
f t
he
 Ja
ns
se
n 
Ph
ar
m
ac
eu
tic
al
s 
sp
ea
ke
r’s
 b
ur
ea
u
Th
e 
m
an
us
cr
ip
t 
w
as
 re
vi
ew
ed
 b
y 
ke
y 
pe
rs
on
ne
l f
ro
m
 
Bo
eh
rin
ge
r I
ng
el
he
im
 
SA
 p
rio
r t
o 
su
bm
iss
io
n
N
VA
F 
= 
 n
on
-v
al
vu
la
r a
tr
ia
l f
ib
ril
la
tio
n;
 A
F 
= 
at
ria
l f
ib
ril
la
tio
n;
 R
E-
LY
 =
 R
an
do
m
iz
ed
 E
va
lu
at
io
n 
of
 L
on
g-
Te
rm
 A
nt
ic
oa
gu
la
tio
n 
Th
er
ap
y;
 S
A
 =
 S
ou
th
 A
fr
ic
a/
n;
 N
O
AC
s =
 n
ov
el 
or
al
 an
tic
oa
gu
la
nt
s; 
IN
R 
= 
 in
te
rn
at
io
na
l n
or
m
al
ise
d 
ra
tio
.
REVIEW
646       August 2018, Vol. 108, No. 8
1. Chugh SS, Havmoeller R, Narayanan K, et al. Worldwide epidemiology of atrial fibrillation: A 
global burden of disease 2010 study. Circulation 2014;129(8):837-847. https://doi.org/10.1161/
CIRCULATIONAHA.113.005119
2. Neal MJ. Medical Pharmacology at a Glance. 6th ed. Chichester, West Sussex: Wiley-Blackwell, 
2009:44-45.
3. Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred Reporting Items for 
Systematic Reviews and Meta-analyses: The PRISMA Statement. PLoS Med 2009;6(7):e1000097. 
https://doi.org/10.1371/journal.pmed.1000097
4. Friedman PA, Rosenberg RD, Hauschka PV, Fitz-James A. A spectrum of partially carboxylated 
prothrombins in the plasmas of coumarin-treated patients. Biochim Biophys Acta 1977;494(1):271-
276. https://doi.org/10.1016/0005-2795(77)90155-6
5. Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G. Oral anticoagulant therapy: 
Antithrombotic Therapy and Prevention of Thrombosis, 9th ed.: American College of Chest Physicians 
Evidence-based Clinical Practice Guidelines. Chest 2012;141(2 Suppl):e44S-e88S. https://doi.
org/10.1378/chest.11-2292
6. Kirkwood TBL. Calibration of reference thromboplastins and standardisation of the prothrombin time 
ratio. Thromb Haemost 1983;49(3):238-244.
7. Holbrook A, Schulman S, Witt DM, et al. Evidence-based management of anticoagulant therapy: 
Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians 
Evidence-Based Clinical Practice Guidelines. Chest 2012;141(2 Suppl):e152S-e184S. https://doi.
org/10.1378/chest.11-2295
8. Samsa GP, Matchar DB. Relationship between test frequency and outcomes of anticoagulation: 
A literature review and commentary with implications for the design of randomized trials of patient self-
management. J Thromb Thrombolysis 2000;9(3):283-292. https://doi.org/10.1023/A:1018778914477
9. Lurie Y, Loebstein R, Kurnik D, Almog S, Halkin H. Warfarin and vitamin K intake in the era 
of pharmacogenetics. Br J Clin Pharmacol 2010;70(2):164-170. https://doi.org/10.1111/j.1365-
2125.2010.03672.x
10. O’Reilly RA. The stereoselective interaction of warfarin and metronidazole in man. N Engl J Med 
1976;295(7):354-357. https://doi.org/10.1056/NEJM197608122950702
11. O’Reilly RA. Lack of effect of fortified wine ingested during fasting and anticoagulant therapy. Arch 
Intern Med 1981;141(4):458-459. https://doi.org/10.1001/archinte.1981.00340040054017
12. Thijssen HHW, Soute BA, Vervoort LM, Claessens JG. Paracetamol (acetaminophen) warfarin 
interaction: NAPQI, the toxic metabolite of paracetamol, is an inhibitor of enzymes in the vitamin K 
cycle. Thromb Haemost 2004;92(4):797-802. https://doi.org/10.1160/TH04-02-0109
13. Cropp JS, Bussey HI. A review of enzyme induction of warfarin metabolism with recommendations for 
patient management. Pharmacotherapy 1997;17(5):917-928. https://doi.org/10.1002/j.1875-9114.1997.
tb03782.x
14. Hughes CA, Freitas A, Miedzinski LJ. Interaction between lopinavir/ritonavir and warfarin. CMAJ 
2007;177(4):357-359. https://doi.org/10.1503/cmaj.061284
15. University of Liverpool. HIV drug interactions. https://www.hiv-druginteractions.org/checker 
(accessed 23 December 2017).
16. University of California. HIV InSite. http://arv.ucsf.edu/insite?page=ar-00-02&post=8&param=120 
(accessed 23 December 2017).
17. Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor 
dabigatran etexilate. Clin Pharmacokinet 2008;47(5):285-295. https://doi.org/10.2165/00003088-
200847050-00001
18. Dager WE, Gosselin RC, Kitchen S, Dwyre D. Dabigatran effects on the international normalized ratio, 
activated partial thromboplastin time, thrombin time, and fibrinogen: A multicenter, in vitro study. 
Ann Pharmacother 2012;46(12):1627-1636. https://doi.org/10.1345/aph.1R179
19. Bounameaux H, Reber G. New oral antithrombotics: A need for laboratory monitoring. Against. 
J Thromb Haemost 2010;8(4):627-630. https://doi.org/10.1111/j.1538-7836.2010.03759.x
20. Samama MM. The mechanism of action of rivaroxaban – an oral, direct factor Xa inhibitor – 
compared with other anticoagulants. Thromb Res 2011;127(6):497-504. https://doi.org/10.1016/j.
thromres.2010.09.008
21. Guyatt GH, Akl EA, Crowther M, Gutterman DD, Schuünemann HJ. Executive summary: 
Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians 
Evidence-Based Clinical Practice Guidelines. Chest 2012;141(2 Suppl):7S-47S. https://doi.org/10.1378/
chest.1412S3
22. Keeling DM, Baglin T, Tait C, et al. Guidelines on oral anticoagulation with warfarin – fourth edition. 
Br J Haematol 2011;154(3):311-324. https://doi.org/10.1111/j.1365-2141.2011.08753.x
23. Laäs D, Naidoo M. An evaluation of warfarin usage of an urban district level hospital in KwaZulu-
Natal. S Afr Med J 2018 (in press).
24. Joint United Nations Programme on HIV/AIDS (UNAIDS). South Africa. http://www.unaids.org/en/
regionscountries/countries/southafrica (accessed 23 December 2017).
25. Awolesi D, Naidoo M, Cassimijee MH. The profile and frequency of known risk factors or comorbidities 
for deep vein thrombosis in an urban district hospital in KwaZulu-Natal. South Afr J HIV Med 
2016;17(1):a425. https://doi.org/10.4102/sajhivmed.v17i1.425
26. Friberg L, Rosenqvist M, Lip GYH. Evaluation of risk stratification schemes for ischaemic stroke and 
bleeding in 182 678 patients with atrial fibrillation: The Swedish Atrial Fibrillation cohort study. Eur Heart 
J 2012;33(12):1500-1510. https://doi.org/10.1093/eurheartj/ehr488
27. Lip GYH, Nieuwlaat R, Pisters R, Lane DA, Crijns HJGM. Refining clinical risk stratification for predicting 
stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: The Euro 
Heart Survey on atrial fibrillation. Chest 2010;137(2):263-272. https://doi.org/10.1378/chest.09-1584
28. Lip GYH, Nielsen PB. Should patients with atrial fibrillation and 1 stroke risk factor (CHA2DS2-VASc 
score 1 in men, 2 in women) be anticoagulated? Yes: Even 1 stroke risk factor confers a real risk of stroke. 
Circulation 2016;133:1498-1503. https://doi.org/10.1161/CIRCULATIONAHA.115.016713
29. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJGM, Lip GYH. A novel user-friendly score (HAS-
BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: The Euro Heart Survey. 
Chest 2010;138(5):1093-1100. https://doi.org/10.1378/chest.10-0134
30. Eikelboom JW, Connolly SJ, Brueckmann M, et al. Dabigatran versus warfarin in patients with mechanical 
heart valves. N Engl J Med 2013;369(13):1206-1214. https://doi.org/10.1056/NEJMoa1300615
31. Hylek EM. Dabigatran and mechanical heart valves – not as easy as we hoped. N Engl J Med 
2013;369(13):1264-1266. https://doi.org/10.1056/NEJMe1310399
32. Carnicelli AP, de Caterina R, Halperin JL, et al. Edoxaban for the prevention of thromboembolism in 
patients with atrial fibrillation and bioprosthetic valves. Circulation 2017;135(13):1273-1275. https://doi.
org/10.1161/CIRCULATIONAHA.116.026714
33. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. 
N Engl J Med 2011;365(10):883-891. https://doi.org/10.1056/NEJMoa1009638
34. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. 
N Engl J Med 2011;365(11):339-354. https://doi.org/10.1056/NEJMoa1107039
35. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. 
N Engl J Med 2009;361(12):1139-1151. https://doi.org/10.1056/NEJMoa0905561
36. Connolly SJ, Pogue J, Eikelboom J, et al. Benefit of oral anticoagulant over antiplatelet therapy in atrial 
fibrillation depends on the quality of international normalized ratio control achieved by centers and 
countries as measured by time in therapeutic range. Circulation 2008;118(20):2029-2137. https://doi.
org/10.1161/CIRCULATIONAHA.107.750000
37. Boehringer Ingelheim Pharmaceuticals I. Praxbind [package insert]. https://docs.boehringer-ingelheim.
com/Prescribing%20Information/PIs/Praxbind/Praxbind.pdf (accessed 29 June 2018).
38. South Africa. Medicines and Related Substances Act 101 of 1965. http://www.hpcsa.co.za/Uploads/editor/
UserFiles/downloads/legislations/acts/medicines_and_related_sub_act_101_of_1965.pdf (accessed 24 
Decem ber 2017).
39. Steiner T, Bohm M, Dichgans M, et al. Recommendations for the emergency management of 
complications associated with the new direct oral anticoagulants (DOACs), apixaban, dabigatran and 
rivaroxaban. Clin Res Cardiol 2013;102(6):399-412. https://doi.org/10.1007/s00392-013-0560-7
40. Cohen DJ, Reynolds MR. Interpreting the results of cost-effectiveness studies. J Am Coll Cardiol 
2008;52(25):2119-2126. https://doi.org/10.1016/j.jacc.2008.09.018
41. Harrington AR, Armstrong EP, Nolan PE, Malone DC. Cost-effectiveness of apixaban, dabigatran, 
rivaroxaban, and warfarin for stroke prevention in atrial fibrillation. Stroke 2013;44(6):1676-1681. https://
doi.org/10.1161/STROKEAHA.111.000402
42. Freeman JV, Zhu RP, Owens DK, et al. Cost-effectiveness of dabigatran compared with warfarin for stroke 
prevention in atrial fibrillation. Ann Intern Med 2011;154(1):1-11. https://doi.org/10.7326/0003-4819-
154-1-201101040-00289
43. Shah SV, Gage BF. Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation. Circulation 
2011;123(22):2562-2570. https://doi.org/10.1161/CIRCULATIONAHA.110.985655
44. Coyle D, Coyle K, Cameron C, et al. Cost-effectiveness of new oral anticoagulants compared with 
warfarin in preventing stroke and other cardiovascular events in patients with atrial fibrillation. Value 
Health 2013;16(4):498-506. https://doi.org/10.1016/j.jval.2013.01.009
45. Canestaro WJ, Patrick AR, Avorn J, et al. Cost-effectiveness of oral anticoagulants for treatment 
of atrial fibrillation. Circ Cardiovasc Qual Outcomes 2013;6(6):724-731. https://doi.org/10.1161/
CIRCOUTCOMES.113.000661
46. Lee S, Anglade MW, Pham D, Pisacane R, Kluger J, Coleman CI. Cost-effectiveness of rivaroxaban 
compared to warfarin for stroke prevention in atrial fibrillation. Am J Cardiol 2012;110(6):845-851. 
https://doi.org/10.1016/j.amjcard.2012.05.011
47. Bergh M, Marais CA, Miller-Jansön H, Salie F, Stander MP. Economic appraisal of dabigatran as first-
line therapy for stroke prevention in atrial fibrillation. S Afr Med J 2013;103(4):241-245. https://doi.
org/10.7196/SAMJ.6471
48. Statistics South Africa. Quarterly Labour Force Survey – QLFS Q3:2017. http://www.statssa.gov.
za/?p=10658 (accessed 15 December 2017).
49. Symons G. Anticoagulation: Where have we come from and where are we going? The evidence for and 
against novel anticoagulants. S Afr Med J 2014;104(2):143-146. https://doi.org/10.7196/SAMJ.7873
Accepted 17 May 2018.
